Abstract
Amyloidosis, caused by a mutation in the transthyretin (TTR) gene, is the most common hereditary type disease. More than 120 mutations have been described, with extensive phenotypic heterogeneity. Val30Met (p.Val50Met) is the most frequent mutation, and patients exhibit polyneuropathy, possibly including cardiac, renal, gastrointestinal, and/or ocular involvement. Val122Ile (p.Val142Ile) is the mutation associated with cardiomyopathy, and few cases have been reported in Brazil. Most individuals are heterozygous for one pathogenic mutation. Herein, we report a compound heterozygote with two pathogenic mutations (Val30Met/ Val122Ile), and a family history of a deceased brother with amyloidosis, who also carried the same TTR gene mutations. The patient presented with neuropathic, cardiac, and renal impairment and a faster disease progression. Cases of the double mutation have been linked to changes in disease presentation. The concomitance of two pathogenic mutations may have contributed to more exuberant manifestations and faster disease progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.
Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.
Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036–43.
Pinto MV, Barreira AA, Bulle AS, Freitas MRG, França MC Jr, Gondim FAA, et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr. 2018;76:609–21.
Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152–8. https://doi.org/10.1136/jnnp-2011-301299.
Castaño A, Drachman B, Judge D, Maurer M. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2014;20:163–78.
Lavigne-Moreira C, Marques V, Gonçalves M, de Oliveira M, Tomaselli P, Nunez J, et al. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst. 2018;23:134–7.
Cruz M, Pinto M, Pinto L, Gervais R, Dias M, Perez C, et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr. 2019;77:96–100.
Matsumoto S, Ueda M, Yamashita T, Amano T, Misumi Y, Tasaki M, Masuda T, Mizukami M, Furuya H, Ando Y. A late-onset case of hereditary transthyretin amyloidosis with a novel compound heterozygous mutation. Amyloid. 2017;24:97–8.
Almeida M, Alves I, Terazaki H, Ando Y, Saraiva M. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun. 2000;270:1024–8.
Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, et al. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun. 1999;264:365–70.
Adams D, Suhr O, Hund E, Obici L, Tournev I, Campistol J, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29:S14–26.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
da Silva-Batista, J.A., Marques Jr, W., Oliveira, M.T.d.J.S. et al. Presence of val30Met and val122ile mutations in a patient with hereditary amyloidosis. J Hum Genet 65, 711–713 (2020). https://doi.org/10.1038/s10038-020-0749-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s10038-020-0749-3
This article is cited by
-
The genetics of cardiac amyloidosis
Heart Failure Reviews (2022)